Ethynyl derivatives
US9359301B2 · kind B2 · utility
2Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2015 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | Apr 17, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D239/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to ethynyl derivatives of formula Iwherein It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.